DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemoglobinopathies Market Size & Forecast By Type, By Therapy, By Diagnosis And Trend Analysis From 2012 To 2022" report to their offering.
Global hemoglobinopathies market is expected to reach over USD 8.82 billion by 2022.
The rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.
The prevalence of hemoglobinopathies is high in low-income countries such as Sub Saharan region and South East Asia. About 85% of the affected population in the U.S. and Europe has ancestral base in these regions.
Governments are collaborating with local institutes to undertake awareness programs for curbing the effect of hemoglobinopathies-related mortality rate. For instance, Thalassemia Data Collection Project and Registry and Surveillance System for Hemoglobinopathies (RuSH) projects were started in 2010 by the Centers for Disease Control and Prevention (CDC).
Low level of hygiene, insufficient healthcare infrastructure, and lesser awareness levels are some key factors attributing to increase in base of target population in low-income regions such as South East Asia, Mediterranean basin, and Africa.
- Gamida Cell
- Alnylam Pharmaceuticals
- Biogen Idec
- Sangamo BioSciences Inc.
- Genetix Pharmaceuticals/Bluebird Bio
- Global Blood Therapeutics Inc.
- Pfizer Inc.
- Mast Therapeutics
- Emmaus Life Sciences, Inc.
- Prolong Pharmaceuticals
- Celgene Corporation
Key Topics Covered:
1 Methodology and Scope
2 Executive Summary
3 Industry Outlook
4 Therapy Outlook
5 Diagnosis Outlook
6 Regional Outlook
7 Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/z6c6gs/hemoglobinopathies